The Zhitong Finance App learned that although Novo Nordisk (NVO.US) announced results for the second quarter of 2026 that exceeded expectations and raised full-year guidance, it did not address Wall Street's biggest concern — can the Danish pharmaceutical giant find a clear path back to sustainable growth as competition in the weight loss drug market intensifies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.